Cryo-Cell International (NYSEAMERICAN:CCEL) Posts Earnings Results

Cryo-Cell International (NYSEAMERICAN:CCEL) issued its earnings results on Friday. The company reported $0.16 EPS for the quarter, FiscalAI reports. The firm had revenue of $7.82 million during the quarter.

Cryo-Cell International Trading Up 4.6%

Shares of NYSEAMERICAN:CCEL traded up $0.19 during midday trading on Friday, hitting $4.36. The company had a trading volume of 5,469 shares, compared to its average volume of 16,295. The firm has a fifty day simple moving average of $4.03 and a 200 day simple moving average of $3.70. The stock has a market cap of $35.14 million, a price-to-earnings ratio of -14.53 and a beta of 0.50. Cryo-Cell International has a 12 month low of $2.72 and a 12 month high of $4.90.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Susquehanna International Group LLP lifted its stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,064 shares of the company’s stock after acquiring an additional 4,046 shares during the quarter. Susquehanna International Group LLP owned approximately 0.17% of Cryo-Cell International worth $45,000 as of its most recent SEC filing. 10.44% of the stock is owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a biotechnology company that provides private stem cell banking and related biorepository services. The company collects, processes and cryogenically stores biological materials obtained primarily from umbilical cord blood and cord tissue, which may be preserved for potential future medical use by the donor or family members.

Its services generally include the coordination of collection kits and medical collection procedures, laboratory processing, testing and long-term storage.